# Neoadjuvant L19IL2/L19TNF- Pivotal Study

> **NCT02938299** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **Philogen S.p.A.** · enrollment: 214 (estimated)

## Conditions studied

- Malignant Melanoma

## Interventions

- **DRUG:** L19IL2 + L19TNF
- **PROCEDURE:** Surgery

## Key facts

- **NCT ID:** NCT02938299
- **Lead sponsor:** Philogen S.p.A.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2016-07-01
- **Primary completion:** 2024-10
- **Final completion:** 2028-12
- **Target enrollment:** 214 (ESTIMATED)
- **Last updated:** 2024-09-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02938299

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02938299, "Neoadjuvant L19IL2/L19TNF- Pivotal Study". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT02938299. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*